Drug Profile
Doxycycline foam - Foamix
Alternative Names: FDX-104; FDX104 antibiotic foamLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Foamix
- Class Antibacterials; Antimalarials; Antineoplastics; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Exanthema
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 03 Apr 2017 Phase-II development for Exanthema (Chemotherapy-induced, Prevention) is ongoing in Israel (Topical, Foam) (Foamix website, April 2017)
- 31 May 2016 Updated efficacy and adverse events data from a phase II trial in Exanthema released by Foamix